Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-06-20
2006-06-20
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391100, C530S387300, C424S130100, C424S178100
Reexamination Certificate
active
07064189
ABSTRACT:
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4496654 (1985-01-01), Katz et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6569642 (2003-05-01), Rauch et al.
patent: 6743625 (2004-06-01), Ni et al.
patent: 2003/0036168 (2003-02-01), Ni et al.
patent: 2003/0073187 (2003-04-01), Ni et al.
patent: 2003/0108516 (2003-06-01), Ni et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 510 691 (1992-10-01), None
patent: 0 857 782 (1998-08-01), None
patent: 0 870 827 (1998-10-01), None
patent: 1 181 319 (2002-02-01), None
patent: 1 192 185 (2002-04-01), None
patent: 1 287 035 (2003-03-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/00423 (1999-01-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12963 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
Reiger et al. (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Paul, Fundamental Immunology, Raven Press, chapter 8, p. 242, 1993.
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Colman ( Research in Immunology 145:33-36, 1994.
Groves et al (Hybridoma 6:71-76, 1987.
Allison, et al., “Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune priviledge upon islet allografts,”Proc. Natl. Acad. Sci. USA, 94:3943-3947 (Apr. 1997).
Allison, et al., “Mechanisms of β cell death in diabetes: a minor role for CD95,”Proc. Natl. Acad. Sci. USA, 95:13818-13822 (Nov. 1998).
Beutler, B and Cerami, A, “Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator,”Ann. Rev. Biochem.57:505-518, Annual Reviews Inc. (1988).
Bodmer, et al., “TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95),”Immunity, 6:79-88 (Jan. 1997).
Boldin, et al., “A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain,”The Journal of Biological Chemistry, 270(14):7795-7798 (Apr. 7, 1995).
Brojatsch, J et al., “CAR1, a TNRF-Related Protein, is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis,”Cell87:845-855, Cell Press (Nov. 1996).
Chapman, BS, “A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-1 and Fas,”FEBS Lett.374:216-220, Elsevier (1995).
Chaudhary et al., “Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and active the NF-kappa B pathway,”Immunity7(6):821-830 (1997).
Chicheportiche, et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis,”The Journal of Biological Chemistry, 272(51):32401-32410 (Dec. 19, 1997).
Chinnaiyan, Am et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science274(5289):990-992 (1996).
Chinnaiyan, et al., “FADD, a novel death domain-containing protein, interacts with the death domain Fas and initiates apoptosis,”Cell, 81:505-512 (May 19, 1995).
Clerici, et al., “Type 1 and type 2 cytokines in HIV infection—A possible role in apoptosis and disease progression,”Annals of Medicine, 29(3):185-188 (1997).
Colman, “Effects of amino acid sequence changes on antibody-antigen Interactions,”Research In Immunology, 145:33-36 (1994).
Database, EMBL Nucleic Acid DB EBI, Hinxton UK, Sequence Accession No. AA100865, Oct. 30, 1996. Hillier et al. “The WashU-Merck EST Project”.
Delgado, C. et al, “Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems,”J. Biochem. Biophys. Methods29:237-250 (1994).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Crit. Rev. Ther. Drug Carrier Sys.9:249-304, CRC Press, Inc. (1992).
Degli-Esposti, et al., “The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain,”Immunity, 7:813-820 (Dec. 1997).
Degli-Esposti, et al., “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family,”J. Exp. Med., 186(7):1165-11700 (Oct. 6, 1977).
Dillman, R.O., “Monoclonal Antibodies for Treating Cancer,”Ann. Internal. Med.111:592-603 (1989).
Duan, et al., “RAIDD is a new ‘death’ adaptor molecule,”Nature, 385:86-89 (Jan. 2, 1997).
Farrow, B. et al., “Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors,”Int. J. Gastrointes. Cancer32(2-3):63-72 (2003).
Fiers, W., “Tumor necrosis factor. Characterization at the molecular, cellular, and in vivo level,”FEBS Lett.285:199-212, Elsevier Science B.V. (1991).
Frankfurt, et al., “Protection from apoptotic cell death by Interleukin-4 is increased by previously treated chronic lymphocytic leukemia patients,”Leukemia Research, 21(1):9-16 (1997).
Gibson, S.B. et al., “Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL,”Mol. Cell Biol.20(1):205-212 (Jan. 2000).
Giovarelli, M. et al., “A ‘stealth effect’: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions,”J. Immunol.163:4886-4893 (1999).
Goeddel, D.V., et al., “Tumor Necrosis Factors: Gene Structure and Biological Activities,”Cold Spring Harb. Symp. Quant. Biol.51(Pt. 1):597-609, Cold Spring Harbor Laboratory Press (1986).
Golstein, P., “Cell death: TRAIL and its receptors,”Curr. Biol.7:R750-R753, Current Biology Ltd. (Dec. 1997).
Gooch, et al., “Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells,”Cancer Research, 58(18):4199-4205 (Sep. 15, 1998).
Goodman, J.W., “Immunog
Albert Vivian R.
Dobson Claire
Rosen Craig A.
Ruben Steven M.
Salcedo Theodora
Helms Larry R.
Human Genome Sciences Inc.
LandOfFree
Antibodies that immunospecifically bind to trail receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that immunospecifically bind to trail receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that immunospecifically bind to trail receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692744